What is the current stock price of Imugene Limited (IUGNF)?

As of the latest market data, Imugene Limited (IUGNF) is trading at $0.12. The stock has seen a loss of -4.47% today.

Does Imugene Limited (IUGNF) pay a dividend?

Based on current data, Imugene Limited does not have a confirmed active dividend policy.

What is the market cap of Imugene Limited?

The current market capitalization of Imugene Limited (IUGNF) is approximately unavailable.

IUGNF

Imugene Limited·Healthcare

0.12

4.472%(−0.01)

Close Price

0.14

19.127%(+0.02)

Pre-Market

Last Updated: — ET

52W L: $0.0652W H: $1.02

IUGNF NEWS

proactiveinvestors.com

Apr 1

Lindian raises A$100M to fast-track Kangankunde expansion and downstream push

Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has secured firm commitments to raise A$100 million through an institutional placement, strengthening its balance...

proactiveinvestors.com

Apr 1

Shares slide after Mkango Resources completes £12.5m fundraise, but oversubscription signals longer-term confidence

The AIM-listed rare earths company upsized its placing after strong demand, though shares fell back on dilution concerns. Shares in Mkango Resources Ltd...

proactiveinvestors.com

Mar 11

Imugene launches $20M capital raise to advance azer-cel clinical program

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has launched a capital raising of up to $20 million through a combination of an institutional placement and a...

proactiveinvestors.com

Mar 11

Premier African Minerals falls 8% as emergency fundraise highlights Zulu project strain

Shares in Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF), the AIM-listed mining company whose stock has lost more than 80% of its value over the past...

proactiveinvestors.com

Mar 10

Imugene highlights azer-cel progress as trial patient enters remission

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is drawing fresh attention to its experimental cancer therapy azer-cel after a Channel 10 news report highlighted...

proactiveinvestors.com

Mar 10

Imugene reports strong early response rates for azer-cel in lymphoma study

Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort...

Company Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-07-05

Beta

2.62

Websitewww.imugene.com↗